**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
First author and presenter: Yuezhi Gu, Brigham and Women's Hospital, Boston MA USA, yugu1@bwh.harvard.edu.
Second author and submitter: Olivier F. Clerc, Brigham and Women's Hospital, Boston MA USA, oclerc@bwh.harvard.edu

**Main Body of the Abstract**
Aim: Patients with systemic AL amyloidosis and cardiomyopathy (AL-CMP) have significant functional limitations. This study aimed to quantify 6-minute walk distance (6MWD) at baseline (treatment initiation), 6 and 12 months, quantify its changes following therapy, and assess its prognostic value in AL amyloidosis.
Material & Methods: Patients with recently diagnosed, biopsy-proven AL amyloidosis were enrolled in a prospective study (clinical trials.gov NCT02641145) and categorized into AL-CMP (abnormal cardiac serum biomarkers) or AL-non-CMP (normal cardiac serum biomarkers and normal LV wall thickness). 6MWD was measured at baseline, 6 and 12 months in AL-CMP, or at baseline and 6 months in AL-non-CMP. Data were compared using Wilcoxon rank-sum test and Wilcoxon signed-rank test (paired). Kaplan-Meier analysis and the log-rank test were used to assess survival (all-cause death).
Results: This study included 81 participants: 61 AL-CMP (75%) and 20 AL-non-CMP (25%). Median age was 61 years (interquartile range [IQR] 57-67 years) and 46 were males (57%). Among participants, 41 AL-CMP (67%) and 18 AL-non-CMP (90%) underwent ≥1 follow-up visit. In the AL-CMP cohort, 22 (27%) died during a median follow-up of 42 months. At baseline, median 6MWD was 308 m (IQR 0-420) in AL-CMP and 462 m (IQR 390-517) in AL-non-CMP (p<0.001), with significant improvement at 12 months in AL-CMP (Figure 1A). Lower baseline 6MWD predicted worse survival (Figure 1B).
Summary & Conclusion: Patients with AL-CMP have severely limited 6MWD compared to AL-non-CMP. 6MWD improves at 12 months after treatment initiation in AL-CMP. 6MWD at baseline is a strong predictor of worse survival.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
First author and presenter: Yuezhi Gu, Brigham and Women's Hospital, Boston MA USA, yugu1@bwh.harvard.edu.
Second author and submitter: Olivier F. Clerc, Brigham and Women's Hospital, Boston MA USA, oclerc@bwh.harvard.edu

**Main Body of the Abstract**
**Aim:** Patients with systemic AL amyloidosis and cardiomyopathy (AL-CMP) have significant functional limitations. This study aimed to quantify 6-minute walk distance (6MWD) at baseline (treatment initiation), 6 and 12 months, quantify its changes following therapy, and assess its prognostic value in AL amyloidosis.
**Material & Methods:** Patients with recently diagnosed, biopsy-proven AL amyloidosis were enrolled in a prospective study (clinical trials.gov NCT02641145) and categorized into AL-CMP (abnormal cardiac serum biomarkers) or AL-non-CMP (normal cardiac serum biomarkers and normal LV wall thickness). 6MWD was measured at baseline, 6 and 12 months in AL-CMP, or at baseline and 6 months in AL-non-CMP. Data were compared using Wilcoxon rank-sum test and Wilcoxon signed-rank test (paired). Kaplan-Meier analysis and the log-rank test were used to assess survival (all-cause death).
**Results:** This study included 81 participants: 61 AL-CMP (75%) and 20 AL-non-CMP (25%). Median age was 61 years (interquartile range [IQR] 57-67 years) and 46 were males (57%). Among participants, 41 AL-CMP (67%) and 18 AL-non-CMP (90%) underwent ≥1 follow-up visit. In the AL-CMP cohort, 22 (27%) died during a median follow-up of 42 months. At baseline, median 6MWD was 308 m (IQR 0-420) in AL-CMP and 462 m (IQR 390-517) in AL-non-CMP (p<0.001), with significant improvement at 12 months in AL-CMP (**Figure 1A**). Lower baseline 6MWD predicted worse survival (**Figure 1B**).
**Summary & Conclusion:** Patients with AL-CMP have severely limited 6MWD compared to AL-non-CMP. 6MWD improves at 12 months after treatment initiation in AL-CMP. 6MWD at baseline is a strong predictor of worse survival.



Functional Capacity in Light Chain Amyloid Cardiomyopathy: Prognostic Value and Changes With Therapy PA135 (#543)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.